[CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER]

A K Nosov; A V Novik; A V Vorobiev; E E Samartseva; S A Reva; I A Baldueva; P A Lushina

[CYTOREDUCTIVE NEPHRECTOMY IN METASTATIC RENAL CELL CANCER]

Vopr Onkol. 2015;61(3):494-8.

[Article in Russian]

Authors

A K Nosov, A V Novik, A V Vorobiev, E E Samartseva, S A Reva, I A Baldueva, P A Lushina

PMID: 26242167

Abstract

The role of cytoreductive nephrectomy in the current era of targeted therapy remains unknown. Two prospective randomized phase III trials (CARMENA and SURTIME) are now opened to evaluate the efficacy of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. So far it is not well known who will and who will not benefit from such surgery.

Publication types

English Abstract

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy
Carcinoma, Renal Cell / secondary
Carcinoma, Renal Cell / surgery*
Chemotherapy, Adjuvant
Clinical Trials, Phase III as Topic
Cytoreduction Surgical Procedures*
Evidence-Based Medicine
Humans
Kidney Neoplasms / drug therapy
Kidney Neoplasms / pathology
Kidney Neoplasms / surgery*
Neoplasm Staging
Nephrectomy*
Randomized Controlled Trials as Topic

Substances

Antineoplastic Agents